Comparison of Low-Dose Rosuvastatin with Atorvastatin in Lipid-Lowering Efficacy and Safety in a High-Risk Pakistani Cohort: An Open-Label Randomized Trial

Table 3

Mean reduction in levels of different lipid fractions.

Variable	Atorvastatin group; (𝑛=63)	Rosuvastatin group; (𝑛=66)	P value*
Absolute reduction from baseline (mmol/L)
Serum total cholesterol	0.77±0.85	1.09±1.10	0.065
Serum triglycerides	0.31±1.01	0.24±0.92	0.657
Serum HDL-C	0.10±0.25	0.29±0.94	0.131
Serum LDL-C	0.54±0.88	0.96±0.96	0.011
Percent reduction from baseline (%)
Serum total cholesterol	13.82±17.10	19.84±19.21	0.062
Serum triglycerides	5.92±40.48	3.52±37.26	0.727
Serum HDL-C	7.63±24.47	5.76±38.14	0.742
Serum LDL-C	13.66±27.99	24.34±31.79	0.045

∗P values refer to the comparison between treatment groups.